// App-Quantinova.ai

1124 : Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Researchers

Presenter

  • Lale Kostakoglu

Principal Investigators

  • Andrew Davies

  • Michael Herold

  • Wolfgang Hiddemann

  • Robert Marcus

  • Judith Trotman

  • Andrea Knapp

  • Federico Mattiello

  • Tina G Nielsen

  • Deniz Sahin

  • Carol Ward

  • Anas Younes

Medical Centers

  • University of Virgina, Charlottesville, VA

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Helios Kliniken, Erfurt, Germany

  • Ludwig-Maximilians-University, University Hospital, Munich, Germany

  • Ipsos Healthcare, London, United Kingdom

  • Concord Hospital, Concord, Australia

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

  • United Kingdom

  • Germany

  • Australia

  • Switzerland

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Rituximab

  • Recil

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • NCT01287741

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved